Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Gemma Medcalf

- PMLiVE

emotive partners with Rare Disease UK for public awareness campaign

Will launch the campaign ahead of next month's Rare Disease Day

- PMLiVE

W2O appoints Jennifer Gottlieb as president

She will take responsibility for W2O wcg, W2O twist and W2O pure

- PMLiVE

The shifting healthcare landscape

Global healthcare is facing massive disruption. Pressures such as an ‘always on’ social media and the new opportunities presented by partnership and collaboration with developers of ground-breaking technologies are contributing...

- PMLiVE

Novartis negotiates ex-US rights to Spark gene therapy

Strikes $170m deal for Luxturna

- PMLiVE

Pharma must do more on antibiotic resistance, Davos meeting hears

But AMR report acknowledges the industry is doing 'better than expected'

- PMLiVE

EMA hands UniQure orphan status first in Huntington’s

The Dutch biotech expects to file the treatment for approval later this year

- PMLiVE

Dr Fiona Marshall heads up MSD’s new UK research facility

She will be based in London and focus on early bioscience discovery

- PMLiVE

Redx Pharma appoints new chief medical officer

Dr Andrew Saunders joins the UK biotech from Lytix Biopharma

- PMLiVE

Flight path: the long-haul journey

Examining the direction of travel for strategic planning

Porterhouse Medical Group charity round-up 2017

Porterhouse Medical Group charity round-up for 2017

As part of the Porterhouse Medical Group’s mission to help improve people’s lives, we use our communications expertise to raise awareness of diseases, and participate in many fund-raising activities for...

Porterhouse Medical Group

Eli Lilly HQ

Lilly claims another EU okay for Taltz

The IL-17 inhibitor can be used alone or in combination with methotrexate for PsA patients

- PMLiVE

Shire says all its studies will publish in open access journals

The Irish biotech says its focus on rare diseases was a key factor behind the decision

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links